Quantcast

Latest Eisai Co. Ltd. Stories

2012-04-23 20:20:01

Tokyo, Apr 23, 2012 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) that the condition for approval of Humira(R) pre-filled syringe 40 mg/0.8 mL for subcutaneous injection (adalimumab [genetical recombination]), a fully human anti-TNF-alpha monoclonal antibody, has been lifted in terms of a drug use results survey (all-case surveillance) for plaque psoriasis and...

2012-04-23 03:13:35

Tokyo, Apr 17, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch the insomnia treatment Lunesta(R) (eszopiclone) in Japan on April 18.Lunesta, originally discovered and developed by Sunovion Pharmaceuticals Inc. ("Sunovion"; formerly Sepracor Inc.; currently a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd.), is the first non-benzodiazepine type GABAA agonist to be launched in Japan in 12 years, and is believed to enhance GABA activity while exerting hypnotic...

2012-04-03 08:20:02

Tokyo, Apr 3, 2012 - (JCN Newswire) - Eisai Co., Ltd. and its diagnostics subsidiary EIDIA Co., Ltd. announced today that EIDIA entered into two separate agreements with medical equipment manufacturers Toshiba Medical Systems Corporation and GE Healthcare Japan Corporation on April 2 for Japan sales of PROTOCO2L, a carbon dioxide insufflation system for CT (computed tomographic) colonography, and carbon dioxide insufflation tube PROTOCO2L Catheter Set (collectively referred to as "the...

2012-04-02 04:20:02

Tokyo, Apr 2, 2012 - (JCN Newswire) - Eisai Co., Ltd. and Minophagen Pharmaceutical Co., Ltd. announced today that they have concluded a license agreement concerning bexarotene (generic name), a treatment for cutaneous T-cell lymphoma (CTCL).Under the terms of the agreement, Eisai shall grant Minophagen Pharmaceutical the exclusive rights to develop and commercialize bexarotene in Asia, Oceania, the Middle East and Eastern Europe, amongst other regions. However, Eisai retains the right of...

2012-02-09 00:20:01

Tokyo, Feb 9, 2012 - (JCN Newswire) - Eisai Co. Ltd entered into an asset purchase agreement with Robert Bosch GmbH (Bosch Group) on February 8, 2012 concerning the transfer of the entire stock and equity interest (100% of total shares issued or equity interest) of the four subsidiaries that comprise the Eisai Group's machinery business to Bosch Group.Under the terms of this agreement, the Eisai Group plans to transfer 100% of total shares held in Eisai Machinery Co. Ltd, the Group's Japan...

2012-01-19 04:20:01

Tokyo, Jan 19, 2012 - (JCN Newswire) - Eisai Co. Ltd and its diagnostics subsidiary EIDIA Co. Ltd announced today that EIDIA will launch LIFE CHECK, a self-monitoring blood glucose meter manufactured by Gunze Limited, on January 27, 2012.LIFE CHECK is a personal self-monitoring blood glucose meter with which diabetes patients can monitor their own blood glucose level by simply inserting a dedicated sensor known as the LIFE CHECK SENSOR into the meter. The meter was developed as a...

2012-01-18 04:20:01

Tokyo, Jan 18, 2012 - (JCN Newswire) - Eisai Co. Ltd announced today that it received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) on January 18, 2012 to market Lunesta (eszopiclone), a product the company has been developing in Japan, as a treatment for insomnia.Lunesta, originally discovered and developed by Sunovion Pharmaceuticals Inc. ("Sunovion"; formerly Sepracor Inc., "Sepracor"; a U.S. subsidiary of Dainippon Sumitomo Pharma Co. Ltd), has been marketed in the...

2012-01-16 04:20:01

Tokyo, Jan 16, 2012 - (JCN Newswire) - Nobelpharma Co. Ltd and Eisai Co. Ltd announced today that they will launch the anticonvulsant agent Fostoin 750 mg for Injection (fosphenytoin sodium hydrate, "fostoin") on January 17. Developed in Japan by Nobelpharma, Fostoin will be marketed by Eisai and co-promoted by both companies under a previously concluded marketing agreement.Fostoin is a water-soluble prodrug of phenytoin injection, a drug that has long been used both in Japan and overseas as...

2011-12-26 00:20:01

Tokyo, Dec 26, 2011 - (JCN Newswire) - Eisai Co. Ltd announced today that it resubmitted the New Drug Application (NDA) for the investigational AMPA receptor antagonist perampanel for partial-onset seizures associated with epilepsy to the U.S. Food and Drug Administration (FDA) on December 22, 2011 (U.S. eastern standard time). This resubmission comes after the FDA issued a Refusal to File letter in July 2011 in which FDA requested reformatting and reanalyses of some datasets in the dossier....

2011-12-21 04:20:01

Tokyo, Dec 21, 2011 - (JCN Newswire) - Eisai Co. Ltd announced today that its pharmaceutical manufacturing and marketing subsidiary Sannova Co. Ltd submitted an application for partial change to the approved label for egg white lysozyme preparation Neuzym to Japan's Ministry of Health, Labour and Welfare (MHLW) on December 21, 2011. The company is seeking approval to remove alveolar pyorrhea and other conditions as approved indications for the product as well as to make changes to dosage and...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related